Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice

Kemnic, 2021 Cadiñanos, 2021, Risks and benefits of reducing the number of drugs to treat HIV-1 infection, Expert Opin Drug Saf, 20, 397, 10.1080/14740338.2021.1887135 Chastain, 2019, Optimizing antiretroviral therapy in treatment-experienced patients living with HIV: a critical review of switch and simplification strategies. An opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy, J Int Assoc Provid AIDS Care, 18, 10.1177/2325958219867325 DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV developed by the DHHS Panel on Antiretroviral Guidelines for Adults 2022, https://clinicalinfo.hiv.gov/sites/default/files/https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf; [Accessed 28 July 2022]. European AIDS Clinical Society. European AIDS Clinical Society (EACS) Guidelines 10.1 October 2020. Version 10.1. 2020, https://www.eacsociety.org/files/guidelines-10.1_30032021_1.pdf; [Accessed 28 July 2022]. Deeks, 2018, Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection, Drugs, 78, 1817, 10.1007/s40265-018-1010-7 Rolle, 2021, Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with, HIV. Medicine (Baltimore), 100, e27330, 10.1097/MD.0000000000027330 Maggiolo, 2021, Bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV aged ≥65 years: week 48 results of a phase 3b, open-label trial, Infect Dis Ther, 10, 775, 10.1007/s40121-021-00419-5 Sax, 2021, Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus, Clin Infect Dis, 73, e485, 10.1093/cid/ciaa988 Andreatta, 2021 Andreatta, 2021 Acosta, 2020, Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) +F/TAF or DTG+F/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance, J Acquir Immune Defic Syndr, 85, 363, 10.1097/QAI.0000000000002454 Micán, 2021 Pelchen-Matthews, 2021, Prevalence and outcomes for heavily treatment-experienced individuals living with human immunodeficiency virus in a European cohort, J Acquir Immune Defic Syndr, 87, 806, 10.1097/QAI.0000000000002635 Henegar, 2019, Identifying heavily treatment-experienced patients in a large administrative claims database Bajema, 2020, Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options, AIDS, 34, 2051, 10.1097/QAD.0000000000002679 Santoro, 2014, Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels, Clin Infect Dis, 58, 1156, 10.1093/cid/ciu020 Armenia, 2014, HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia, J Antimicrob Chemother, 70, 1865, 10.1093/jac/dkv029 Molina, 2018, Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial, Lancet HIV, 1, 1 Chang, 2021, Outcomes after switching to BIC/FTC/TAF in patients with virological failure to protease inhibitors or non-nucleoside reverse transcriptase inhibitors: a real-world cohort study, Infect Drug Resist, 14, 4877, 10.2147/IDR.S331647 D'Antoni, 2021, Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) efficacy in participants with pre-existing primary integrase inhibitor resistance through 48 weeks of phase 3 clinical trials, J Acquir Immune Defic Syndr, 89, 433, 10.1097/QAI.0000000000002888 Gagliardini, 2018, Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study, Open Forum Infect Dis, 5, ofy113, 10.1093/ofid/ofy113 Ciccullo, 2021, Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding, J Acquir Immune Defic Syndr, 88, 234, 10.1097/QAI.0000000000002787 Chabria, 2014, Deep sequencing of HIV: clinical and research applications, Annu Rev Genomics Hum Genet, 15, 295, 10.1146/annurev-genom-091212-153406 Arias, 2018, Sanger and next generation sequencing approaches to evaluate HIV-1 virus in blood compartments, Int J Environ Res Public Health, 15, 1697, 10.3390/ijerph15081697